# Junta clínica — PT-pseudo_f4ea752ca1bb (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_f4ea752ca1bb",
  "pid": "PT-pseudo_f4ea752ca1bb",
  "task": 1,
  "psa": 6.9,
  "age": 79,
  "months": 1,
  "pirads": "4",
  "psad": 0.159,
  "psav": 1.53,
  "psap": 6.6,
  "vol": 43.34,
  "dre": "Nodus",
  "bx": "None",
  "cspca": 0.7682602,
  "medhx": "COPD",
  "meds": "tiotropium, salbutamol PRN",
  "notes": "PSA 6.9 ng/mL. PI-RADS 4. PSAD 0.16. Prostate volume 43 mL. DRE nodus. csPCa 0.77.",
  "pmhx": [
    "COPD"
  ],
  "allergies": [],
  "vitals": {
    "weight": "84 kg",
    "height": "188 cm",
    "bmi": "23.8",
    "bp": "125/84 mmHg",
    "hr": "75 bpm",
    "smoking": "Current smoker (15 pack-yr)",
    "last_dental": "3 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "21 Jan 2025",
  "enc_ref": "Dr. F. de Boer (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Persistent elevation of the prostate-specific antigen level to 6.9 ng/mL prompted this consultation after recent multiparametric imaging."
    },
    {
      "s": "History",
      "t": "A 79-year-old retired civil servant entered the system in spring 2023 after an initial prostate-specific antigen reading of 3.7 ng/mL. Surveillance has continued given the steady upward trend. Following the passing of his spouse several years prior, he now resides solo, depending on his daughter for mail handling while maintaining full independence in daily routines. Lower urinary tract complaints remain slight, reflected by an IPSS score of 3. Respiratory management involves tiotropium alongside salbutamol administered as required for his COPD. Beyond urological matters, he recently finished a standard colonoscopy screening and visited vascular surgery regarding asymptomatic varicose veins. Daily gardening sustains his activity level, he completely avoids alcohol, and maintains a current smoking status with a 15 pack-year history. He explicitly denies haematuria, unexplained weight loss, or bone pain."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: firm, mobility: fixed, asymmetry: prominent. A discrete nodule resides within the right posterior peripheral zone, accompanied by overall gland enlargement. General assessment shows clear lung fields and a regular cardiac rhythm. Blood pressure registers at 125/84 mmHg, with a heart rate of 75 bpm."
    }
  ],
  "occupation": "retired civil servant",
  "marital": "Widowed",
  "living": "Lives alone",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Gastroenterology — surveillance colonoscopy",
    "Vascular surgery — varicose veins consult"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Gardening, no structured exercise",
  "ipss": "IPSS score: 3/35 (mild LUTS)",
  "admin": "Daughter manages communication; CC on letters with patient consent.",
  "mri_hospital": "Ziekenhuis Gelderse Vallei (Ede)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_f4ea752ca1bb
Task: 1

Encounter: Urology - outpatient on 21 Jan 2025.
Referrer: Dr. F. de Boer (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 79-year-old male
  - PSA: 6.9 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.159 ng/mL²
  - PSA velocity: 1.53 ng/mL/yr
  - Prior PSA: 6.6 ng/mL
  - Prostate volume: 43.34 mL
  - Months since last PSA: 1
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7682602 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: COPD
  - Problem list / PMHx: COPD
  - Current medication: tiotropium, salbutamol PRN
  - Allergies: NKA
  - Additional notes: PSA 6.9 ng/mL. PI-RADS 4. PSAD 0.16. Prostate volume 43 mL. DRE nodus. csPCa 0.77.

Vitals: weight 84 kg, height 188 cm, BMI 23.8, BP 125/84 mmHg, HR 75 bpm. Smoking: Current smoker (15 pack-yr).

Chief complaint: Persistent elevation of the prostate-specific antigen level to 6.9 ng/mL prompted this consultation after recent multiparametric imaging.

History: A 79-year-old retired civil servant entered the system in spring 2023 after an initial prostate-specific antigen reading of 3.7 ng/mL. Surveillance has continued given the steady upward trend. Following the passing of his spouse several years prior, he now resides solo, depending on his daughter for mail handling while maintaining full independence in daily routines. Lower urinary tract complaints remain slight, reflected by an IPSS score of 3. Respiratory management involves tiotropium alongside salbutamol administered as required for his COPD. Beyond urological matters, he recently finished a standard colonoscopy screening and visited vascular surgery regarding asymptomatic varicose veins. Daily gardening sustains his activity level, he completely avoids alcohol, and maintains a current smoking status with a 15 pack-year history. He explicitly denies haematuria, unexplained weight loss, or bone pain.

Physical examination: DRE — texture: firm, mobility: fixed, asymmetry: prominent. A discrete nodule resides within the right posterior peripheral zone, accompanied by overall gland enlargement. General assessment shows clear lung fields and a regular cardiac rhythm. Blood pressure registers at 125/84 mmHg, with a heart rate of 75 bpm.

Patient info: retired civil servant; Widowed; Lives alone.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Gardening, no structured exercise; IPSS score: 3/35 (mild LUTS).

Recent other appointments: Gastroenterology — surveillance colonoscopy; Vascular surgery — varicose veins consult.
Admin: Daughter manages communication; CC on letters with patient consent.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.68
  uncertainty  +/- 0.08 epistemic (95% band 0.52-0.85); among patients I cannot tell apart the outcome was 0.90 of 1.00 mixed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers BIOPSY.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 24 labelled men in this same situation (None prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.88: PI-RADS 5, PSA 7.6, PSAD 0.236, age 78, DRE Nodus -> BIOPSY (borderline). He wrote: "This is borderline. A P5 but old man and moderately PSA with no symptoms."
  2. distance 2.16: PI-RADS 4, PSA 4.8, PSAD 0.086, age 65, DRE Nodus -> BIOPSY (clear). He wrote: "P4 in patient 65 years."
  3. distance 2.56: PI-RADS 4, PSA 9.3, PSAD 0.296, age 66, DRE Normal -> BIOPSY (clear). He wrote: "P4 in 66 year old patient."

PRECEDENT: BIOPSY (weighted vote 1.00 for biopsy). Distance-weighted precedent is strong here (0.92 leave-one-out).

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 24 labelled traces in this situation (None prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: bx=noted, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines link the PI-RADS score to the decision for biopsy. The guideline suggests that a PI-RADS threshold of $\ge 3$ is used to trigger a biopsy. It also notes that using a threshold of $\ge 4$ would have avoided a significant proportion of biopsies while missing some cancer.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is based on a broad panel of variables, but the guideline suggests that the decision should be more directly tied to the imaging findings. The guideline makes decisive that the PI-RADS score is the primary factor for triggering the decision. The precedent suggests that the decision is heavily influenced by the PI-RADS score, and other factors like PSA or DRE findings are secondary to the imaging classification.

WHAT WE STILL NEED
The panel already contains the PI-RADS score of 4, which is above the threshold of 3 mentioned in the guideline. The panel also contains the prior-biopsy status, which is "None," which is a factor noted in the guideline regarding biopsy-naïve patients. The panel also contains the PSA density of 0.159 ng/mL², which is relevant as it relates to the PSA-D categories mentioned in the guideline. The panel also contains the DRE finding of "Nodus," which is a factor noted in the guideline regarding clinical suspicion.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case strongly points towards biopsy based on the PI-RADS score and the cohort data, but we need to establish the specific details from the radiology report and PSA trend.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone described in the mpMRI prose?
  psa_trend (get_psa_trend) -> What is the trend (rising, flat, or falling) of the serial PSA values?
  previous_notes (get_previous_notes) -> What is the management context regarding prior biopsy status, surveillance protocol, and planned treatment?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the specific description of the lesion size and zone from the radiology report?
  Q2. What is the trend of the serial PSA values?
  Q3. Does the previous notes section specify any details regarding surveillance protocols or prior biopsy planning?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: Multiparametric MRI of the Prostate | Date: 15 January 2025 | Facility: Ziekenhuis Gelderse Vallei (Ede)
What is the lesion size and zone described in the mpMRI prose? The focal hypointense area is in the right posterior peripheral zone, spanning approximately 18 x 14 x 16 mm.
psa_trend
What is the trend (rising, flat, or falling) of the serial PSA values? The trend is rising, with values from 2.0 ng/mL in Apr 2023 to 6.9 ng/mL in Jan 2025.
previous_notes
What is the management context regarding prior biopsy status, surveillance protocol, and planned treatment? Prior biopsy status was "None". Surveillance was continued given the steady upward trend, and a multiparametric MRI was coordinated.

WHAT I DID NOT OPEN
nothing

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS score of 4, which is above the EAU threshold of 3.
The mpMRI report describes a focal lesion with restricted diffusion and early enhancement.
The PSA trend shows a clear rising trajectory from 3.7 ng/mL to 6.9 ng/mL over two years.
Findings that argue AGAINST sampling this patient now:
Prior biopsy status is "None".
The DRE finding was "Nodus" (which is not explicitly defined as suspicious in the context of the panel).

WHERE THIS LEANS
The imaging findings (PI-RADS 4) and the rising PSA trend strongly support a biopsy, aligning with the EAU guideline's primary reliance on imaging classification.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 6.90 ng/mL over 4 points spanning 21 months; velocity +2.79 ng/mL per year; doubling time about 12 months.
PROJECTION at 6 months: 10.3 ng/mL, conformal 95% band 3.0-36.1.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.63
  uncertainty  +/- 0.10 epistemic (95% band 0.43-0.84), of which 0.01 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 56% of the time over the 25 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.68  ('firm' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.63  ('supports' tier, fusion_nolab)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=1.00  (k=3 precedents)
  EXPERT-COHORT      BIOPSY  (rule pirads_ge_3)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (pirads_ge_3) — carried by EXPERT-COHORT.
PANEL ANSWER: BIOPSY. It matched the reading urologist in 24 of 24 labelled cases in exactly this situation (never biopsied).

Confidence the trace model expects here: clear. Weights it expects: bx=noted, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—radiology_report, psa_trend, and previous_notes—directly address all three moderator questions.

ALIGNMENT WITH THE PANEL
The retrieved evidence strongly aligns with the PANEL-PROTOCOL's answer of BIOPSY, as the rising PSA trend and the PI-RADS 4 score (which is $\ge 3$) are key factors supporting this decision.

THE OPEN QUESTIONS, ONE BY ONE
Q1. The radiology report states the focal hypointense area is in the right posterior peripheral zone, spanning approximately 18 x 14 x 16 mm.
Q2. The PSA trend is rising, with values from 2.0 ng/mL in Apr 2023 to 6.9 ng/mL in Jan 2025.
Q3. The previous notes state that prior biopsy status was "None" and surveillance was continued given the steady upward trend.

WHAT CARRIES WEIGHT, AND WHY
The PI-RADS score of 4 is the most decisive variable as it directly triggers the cohort criterion in the panel protocol. The rising PSA trend further supports the clinical suspicion, and the prior biopsy status being "None" is a relevant factor noted by the experts.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy, as the retrieved evidence, particularly the PI-RADS 4 and the rising PSA trend, strongly supports the panel's conclusion.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the PI-RADS score of 4 directly triggers the cohort criterion, which has a strong track record in this situation. This decision is further supported by the rising PSA trend, which indicates disease progression, and the fact that the patient has never been biopsied previously. The evidence converged on a positive recommendation for sampling.

What carried weight: bx=noted, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
